Literature DB >> 26825446

BleeMACS: rationale and design of the study.

Fabrizio D'Ascenzo1, Emad Abu-Assi, Sergio Raposeiras-Roubín, José Paulo Simao Henriques, Jorge Saucedo, José Ramon González-Juanatey, Stephen B Wilton, Wouter J Kikkert, Iván Nuñez-Gil, Albert Ariza-Sole, Xiantao Song, Dimitrios Alexopoulos, Christoph Liebetrau, Tetsuma Kawaji, Claudio Moretti, Zenon Huczek, Shao-Ping Nie, Toshiharu Fujii, Luis Claudio Correia, Masa-Aki Kawashiri, José María García-Acuña, Danielle Southern, Emilio Alfonso, Belén Terol, Alberto Garay, Dongfeng Zhang, Yalei Chen, Ioanna Xanthopoulou, Neriman Osman, Helge Möllmann, Hiroki Shiomi, Francesca Giordana, Silvia Scarano, Fiorenzo Gaita, Michal Kowara, Krzysztof J Filipiak, Xiao Wang, Yan Yan, Jing-Yao Fan, Yuji Ikari, Takuya Nakahayshi, Kenji Sakata, Masakazu Yamagishi, Oliver Kalpak, Sasko Kedev.   

Abstract

BACKGROUND: Bleeding events after an acute coronary syndrome have a negative impact on prognosis. Available risk scores are limited by suboptimal accuracy, prediction of only in-hospital events and absence of patients treated with new antiplatelet agents in the current era of widespread use of percutaneous coronary intervention.
DESIGN: The BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) project is a multicenter investigator-initiated international retrospective registry that enrolled more than 15 000 patients discharged with a definitive diagnosis of acute coronary syndrome and treated with percutaneous revascularization. The primary end point is the incidence of major bleeding events requiring hospitalization and/or red cell transfusion concentrates within 1 year. An integer risk score for bleeding within the first year after hospital discharge will be developed from a multivariate competing-risks regression.
CONCLUSION: The BleeMACS registry collaborative will allow development and validation of a risk score for prediction of major bleeding during follow-up for patients receiving contemporary therapies for acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825446     DOI: 10.2459/JCM.0000000000000362

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  4 in total

Review 1.  Risk Stratification in Patients with Coronary Artery Disease: A Practical Walkthrough in the Landscape of Prognostic Risk Models.

Authors:  Sergio Buccheri; Paolo D'Arrigo; Gabriele Franchina; Davide Capodanno
Journal:  Interv Cardiol       Date:  2018-09

2.  Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome.

Authors:  Yan Yan; Xiao Wang; Jing-Yao Fan; Shao-Ping Nie; Sergio Raposeiras-Roubín; Emad Abu-Assi; Jose P Simao Henriques; Fabrizio D'Ascenzo; Jorge Saucedo; José R González-Juanatey; Stephen B Wilton; Wouter J Kikkert; Iván Nuñez-Gil; Albert Ariza-Sole; Xian-Tao Song; Dimitrios Alexopoulos; Christoph Liebetrau; Tetsuma Kawaji; Claudio Moretti; Zenon Huczek; Toshiharu Fujii; Luis C Correia; Masa-Aki Kawashiri; Sasko Kedev
Journal:  J Geriatr Cardiol       Date:  2016-03       Impact factor: 3.327

3.  Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice.

Authors:  Yan Yan; Xiao Wang; Jing-Yao Fan; Shao-Ping Nie; Sergio Raposeiras-Roubín; Emad Abu-Assi; Jose P Simao Henriques; Fabrizio D'Ascenzo; Jorge Saucedo; José R González-Juanatey; Stephen B Wilton; Wouter J Kikkert; Iván Nuñez-Gil; Albert Ariza-Sole; Xian-Tao Song; Dimitrios Alexopoulos; Christoph Liebetrau; Tetsuma Kawaji; Claudio Moretti; Zenon Huczek; Toshiharu Fujii; Luis Cl Correia; Masa-Aki Kawashiri; Sasko Kedev
Journal:  J Geriatr Cardiol       Date:  2017-11       Impact factor: 3.327

4.  Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke.

Authors:  Dongfeng Zhang; Xiantao Song; Sergio Raposeiras-Roubín; Emad Abu-Assi; Jose Paulo Simao Henriques; Fabrizio D'Ascenzo; Jorge Saucedo; José Ramón González-Juanatey; Stephen B Wilton; Wouter J Kikkert; Iván Nuñez-Gil; Albert Ariza-Sole; Dimitrios Alexopoulos; Christoph Liebetrau; Tetsuma Kawaji; Claudio Moretti; Zenon Huczek; Shaoping Nie; Toshiharu Fujii; Luis Correia; Masa-Aki Kawashiri; Danielle Southern; Oliver Kalpak
Journal:  Ther Adv Chronic Dis       Date:  2021-09-29       Impact factor: 5.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.